SK19192000A3 - Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia - Google Patents

Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia Download PDF

Info

Publication number
SK19192000A3
SK19192000A3 SK1919-2000A SK19192000A SK19192000A3 SK 19192000 A3 SK19192000 A3 SK 19192000A3 SK 19192000 A SK19192000 A SK 19192000A SK 19192000 A3 SK19192000 A3 SK 19192000A3
Authority
SK
Slovakia
Prior art keywords
paroxetine
pharmaceutically acceptable
core
substance
acceptable salt
Prior art date
Application number
SK1919-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Martin X. Steiner
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SK19192000A3 publication Critical patent/SK19192000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1919-2000A 1998-06-16 1999-06-16 Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia SK19192000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (1)

Publication Number Publication Date
SK19192000A3 true SK19192000A3 (sk) 2001-05-10

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1919-2000A SK19192000A3 (sk) 1998-06-16 1999-06-16 Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia

Country Status (20)

Country Link
EP (1) EP1087766A4 (ja)
JP (1) JP2002518330A (ja)
KR (1) KR20010052895A (ja)
CN (1) CN1305379A (ja)
AP (1) AP2000002002A0 (ja)
AU (1) AU740749B2 (ja)
BG (1) BG105127A (ja)
BR (1) BR9911150A (ja)
CA (1) CA2335236A1 (ja)
CZ (1) CZ20004698A3 (ja)
EA (1) EA003584B1 (ja)
GB (1) GB9812941D0 (ja)
HU (1) HUP0102507A3 (ja)
IL (1) IL139943A0 (ja)
NO (1) NO20006383D0 (ja)
NZ (1) NZ508532A (ja)
PL (1) PL345261A1 (ja)
SK (1) SK19192000A3 (ja)
WO (1) WO1999065491A1 (ja)
ZA (1) ZA200007396B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
IL162458A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method

Also Published As

Publication number Publication date
HUP0102507A3 (en) 2003-12-29
PL345261A1 (en) 2001-12-03
HUP0102507A2 (hu) 2002-05-29
JP2002518330A (ja) 2002-06-25
ZA200007396B (en) 2002-02-27
AP2000002002A0 (en) 2000-12-31
CA2335236A1 (en) 1999-12-23
CN1305379A (zh) 2001-07-25
BR9911150A (pt) 2001-03-06
NO20006383L (no) 2000-12-14
EP1087766A1 (en) 2001-04-04
AU740749B2 (en) 2001-11-15
KR20010052895A (ko) 2001-06-25
NO20006383D0 (no) 2000-12-14
CZ20004698A3 (cs) 2002-02-13
EA003584B1 (ru) 2003-06-26
NZ508532A (en) 2003-08-29
AU4688599A (en) 2000-01-05
EA200100041A1 (ru) 2001-06-25
BG105127A (en) 2001-11-30
EP1087766A4 (en) 2001-11-21
GB9812941D0 (en) 1998-08-12
WO1999065491A1 (en) 1999-12-23
IL139943A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
EP2046285B1 (en) Granule and orally disintegrating tablet comprising oxycodone
US20040220250A1 (en) Novel oral dosage form for carvedilol
RU2401109C2 (ru) Таблетированный препарат с замедленным высвобождением для вертиго
CA2314433A1 (en) Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance
US20060153925A1 (en) Novel solid pharmaceutical composition comprising amisulpride
US6855336B2 (en) Omeprazole formulation
FI117373B (fi) Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
US20070160664A1 (en) Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent
JP2002509882A (ja) フルオキセチンおよびそのエナンチオマーの安定した投薬剤形
RU2108097C1 (ru) Фармацевтическая композиция, содержащая соль ранитидина и карбоксилата висмута, и способ ее получения
US6300343B1 (en) Method of treatment
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
US20020173522A1 (en) Pharmaceutical compositions comprising norastemizole
JP2004516234A (ja) コア製剤
EP1560568B1 (en) Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate
MXPA00012626A (en) Method of treatment
EP1035869A1 (en) Chemically and thermally stable norastemizole formulations